OTCMKTS:SOLTF Nxera Pharma (SOLTF) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free SOLTF Stock Alerts $9.72 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$9.72▼$9.7250-Day Range$8.65▼$13.4352-Week Range$8.56▼$22.78VolumeN/AAverage Volume2,905 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Nxera Pharma alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Nxera Pharma Stock (OTCMKTS:SOLTF)Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.Read More SOLTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SOLTF Stock News HeadlinesApril 17, 2024 | finance.yahoo.comNxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU PlanApril 15, 2024 | msn.comNxera and Handok partner for PIVLAZ supply in South KoreaApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 15, 2024 | nasdaq.comNxera Pharma Announces Supply And Distribution Deal With Handok For PIVLAZ In South KoreaApril 15, 2024 | finance.yahoo.comNxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South KoreaApril 8, 2024 | finance.yahoo.comNxera Pharma joins the World Orphan Drug AllianceApril 3, 2024 | finance.yahoo.comNxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APACMarch 31, 2024 | globenewswire.comNxera Pharma is the New Name for Sosei GroupApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. March 27, 2024 | finance.yahoo.comSosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera PharmaMarch 20, 2024 | finance.yahoo.comSosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel DiseaseMarch 11, 2024 | finance.yahoo.comBoehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophreniaMarch 6, 2024 | finance.yahoo.comSosei Heptares to receive US$2.5 million milestone payment from Formosa PharmaceuticalsMarch 1, 2024 | finance.yahoo.comSosei Group Corporation (SOLTF)February 15, 2024 | globenewswire.comSosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head OfficeFebruary 13, 2024 | finance.yahoo.comSosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023January 22, 2024 | finance.yahoo.comSosei Heptares Webinar Presentation for FY2023 Financial ResultsJanuary 5, 2024 | finance.yahoo.comSosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating OfficerDecember 21, 2023 | finance.yahoo.comSosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare ConferenceDecember 7, 2023 | finance.yahoo.comSosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South KoreaDecember 6, 2023 | finance.yahoo.comSosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical StudiesNovember 24, 2023 | finance.yahoo.comSosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel DiseaseNovember 14, 2023 | morningstar.comSosei Group Corp 4565November 10, 2023 | msn.comSosei Group reports Q3 resultsNovember 10, 2023 | finance.yahoo.comSosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal DiseasesNovember 10, 2023 | finance.yahoo.comSosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023November 7, 2023 | finance.yahoo.comSosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2023See More Headlines Receive SOLTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nxera Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:SOLTF CUSIPN/A CIKN/A Webwww.sosei.com Phone(135) 210-3290FaxN/AEmployees350Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Shinichi Tamura (Age 75)Founder & Chairman of the Board Comp: $1.54MMr. Christopher Cargill (Age 40)Representative Executive Officer, President, CEO & Director Comp: $1.32MMr. Hironoshin Nomura (Age 41)Executive Officer, Executive VP & CFO Mr. Toshihiro MaedaChief Operating OfficerMr. Kieran Johnson F.C.A. (Age 55)Executive Officer, Executive VP & Chief Accounting Officer Dr. Miles CongreveChief Scientific OfficerMr. Kazuhiko Yoshizumi (Age 70)Executive Officer, Executive VP & Chief Compliance Officer Shinichiro NishishitaVP of Investor Relations & Head of Regulatory DisclosuresStacey SouthallAssociate Director & Head of BiophysicsMs. Candelle Chong (Age 35)Executive Officer, Executive VP & Chief of Staff More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors SOLTF Stock Analysis - Frequently Asked Questions Should I buy or sell Nxera Pharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nxera Pharma in the last year. There are currently 2 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "sell" SOLTF shares. View SOLTF analyst ratings or view top-rated stocks. How have SOLTF shares performed in 2024? Nxera Pharma's stock was trading at $10.00 at the beginning of 2024. Since then, SOLTF stock has decreased by 2.8% and is now trading at $9.72. View the best growth stocks for 2024 here. How do I buy shares of Nxera Pharma? Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SOLTF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nxera Pharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
